Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 30,497 | 6,116 | 24,148 |
| Samples | 4,286 | 1,323 | 2,924 |
| Peptides | 3,600 | 1,260 | 2,729 |
Function
MUC4 · Mucin 4, cell surface associated
The major constituents of mucus, the viscous secretion that covers epithelial surfaces such as those in the trachea, colon, and cervix, are highly glycosylated proteins called mucins. These glycoproteins play important roles in the protection of the epithelial cells and have been implicated in epithelial renewal and differentiation. This gene encodes an integral membrane glycoprotein found on the cell surface, although secreted isoforms may exist. At least two dozen transcript variants of this gene have been found, although for many of them the full-length transcript has not been determined or they are found only in tumor tissues. This gene contains a region in the coding sequence which has a variable number (>100) of 48 nt tandem repeats. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
9 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000463781 | Q99102 | 15,008 | 3,562 |
| ENST00000475231 | Q99102-10 | 14,132 | 3,350 |
| ENST00000346145 | Q99102-13 | 684 | 469 |
| ENST00000349607 | Q99102-12 | 651 | 442 |
| ENST00000627146 | A0A0G2JQK9* | 16 | 16 |
| ENST00000625520 | A0A0G2JRK4* | 3 | 3 |
| ENST00000478156 | Q99102-3 | 1 | 1 |
| ENST00000627411 | A0A0G2JR43* | 1 | 1 |
| ENST00000631201 | A0A0G2JRJ6* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 2500 amino-acid changes on canonical ENST00000463781 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MUC4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MUC4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 24/40 60% | 0/0 0% |
| Chronic Myelogenous Leukemia | 13/25 52% | 0/0 0% |
| Oral Cavity Carcinoma | 28/54 52% | 0/0 0% |
| Acute Myeloid Leukemia | 35/90 39% | 0/0 0% |
| Glioblastoma | 38/98 39% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 8/26 31% | 0/0 0% |
| Endometrial Carcinoma | 27/42 64% | 122/612 20% |
| Melanoma | 104/210 50% | 258/1899 14% |
| Neuroendocrine Tumour | 83/154 54% | 39/577 7% |
| Cervical Carcinoma | 14/35 40% | 61/422 14% |
| Osteosarcoma | 12/45 27% | 20/166 12% |
| Hodgkins Lymphoma | 9/16 56% | 11/122 9% |
| Bladder Carcinoma | 25/58 43% | 115/956 12% |
| Other Solid Cancers | 39/94 41% | 177/1515 12% |
| Mesothelioma | 18/62 29% | 11/165 7% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 16/133 12% |
| Non-Small Cell Lung Carcinoma | 101/304 33% | 96/1390 7% |
| Rhabdomyosarcoma | 12/33 36% | 11/171 6% |
| Chondrosarcoma | 6/14 43% | 3/75 4% |
| Gastric Carcinoma | 35/74 47% | 153/1809 8% |
| Colorectal Carcinoma | 76/143 53% | 260/3239 8% |
| Thyroid Gland Carcinoma | 24/45 53% | 122/1592 8% |
| Plasma Cell Myeloma | 25/44 57% | 6/305 2% |
| Esophageal Squamous Cell Carcinoma | 32/51 63% | 193/2550 8% |
| Kidney Carcinoma | 43/85 51% | 121/1862 6% |
| Squamous Cell Lung Carcinoma | 23/57 40% | 50/810 6% |
| Germ Cell Tumour | 13/25 52% | 3/169 2% |
| Burkitts Lymphoma | 18/32 56% | 0/196 0% |
| Ewings Sarcoma | 24/63 38% | 1/262 0% |
| Unknown | 3/10 30% | 0/29 0% |
Mutation Distribution
Where MUC4 is mutated · all tissues, split by cell line vs tissue
How many mutations in MUC4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 30,497 mutations in MUC4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|